300 related articles for article (PubMed ID: 33293374)
1. Genomic Characterization of
Garrido-Castro AC; Spurr LF; Hughes ME; Li YY; Cherniack AD; Kumari P; Lloyd MR; Bychkovsky B; Barroso-Sousa R; Di Lascio S; Jain E; Files J; Mohammed-Abreu A; Krevalin M; MacKichan C; Barry WT; Guo H; Xia D; Cerami E; Rollins BJ; MacConaill LE; Lindeman NI; Krop IE; Johnson BE; Wagle N; Winer EP; Dillon DA; Lin NU
Clin Cancer Res; 2021 Feb; 27(4):1105-1118. PubMed ID: 33293374
[TBL] [Abstract][Full Text] [Related]
2. The clinicomolecular landscape of de novo versus relapsed stage IV metastatic breast cancer.
Seltzer S; Corrigan M; O'Reilly S
Exp Mol Pathol; 2020 Jun; 114():104404. PubMed ID: 32067942
[TBL] [Abstract][Full Text] [Related]
3. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.
Malmgren JA; Mayer M; Atwood MK; Kaplan HG
Breast Cancer Res Treat; 2018 Jan; 167(2):579-590. PubMed ID: 29039120
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand.
Lao C; Kuper-Hommel M; Elwood M; Campbell I; Edwards M; Lawrenson R
Breast Cancer; 2021 Mar; 28(2):387-397. PubMed ID: 33044617
[TBL] [Abstract][Full Text] [Related]
5. Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients.
McKenzie HS; Maishman T; Simmonds P; Durcan L; ; Eccles D; Copson E
Br J Cancer; 2020 May; 122(11):1618-1629. PubMed ID: 32231292
[TBL] [Abstract][Full Text] [Related]
6. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
[TBL] [Abstract][Full Text] [Related]
7. Genomic Characterization of De Novo Metastatic Breast Cancer.
Mullangi S; Vasan N
Clin Breast Cancer; 2022 Feb; 22(2):98-102. PubMed ID: 34949553
[TBL] [Abstract][Full Text] [Related]
8. HR
Torrisi R; Jacobs F; Miggiano C; De Sanctis R; Santoro A
Drugs Context; 2023; 12():. PubMed ID: 36926051
[TBL] [Abstract][Full Text] [Related]
9. Survival among patients with untreated metastatic breast cancer: "What if I do nothing?".
Plichta JK; Thomas SM; Wang X; McDuff SGR; Kimmick G; Hwang ES
Breast Cancer Res Treat; 2024 Jun; 205(2):333-347. PubMed ID: 38438700
[TBL] [Abstract][Full Text] [Related]
10. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.
Müller V; Hein A; Hartkopf AD; Fasching PA; Kolberg HC; Hadji P; Tesch H; Häberle L; Ettl J; Lüftner D; Wallwiener M; Beckmann MW; Schneeweiss A; Belleville E; Uhrig S; Wimberger P; Hielscher C; Meyer J; Wurmthaler LA; Kurbacher CM; Wuerstlein R; Untch M; Janni W; Taran FA; Lux MP; Wallwiener D; Brucker SY; Fehm TN; Michel LL
Eur J Cancer; 2022 Sep; 172():13-21. PubMed ID: 35728342
[TBL] [Abstract][Full Text] [Related]
11. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
12. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
[TBL] [Abstract][Full Text] [Related]
13. Utilization and outcomes of the 21-gene recurrence score in de novo metastatic breast cancer.
Yang SP; Liu K; Li Y; Li GQ; Li JY; Lin YY; Wu SG
Expert Rev Mol Diagn; 2024; 24(1-2):99-106. PubMed ID: 38166613
[TBL] [Abstract][Full Text] [Related]
14. The Genomic Landscape of Male Breast Cancers.
Piscuoglio S; Ng CK; Murray MP; Guerini-Rocco E; Martelotto LG; Geyer FC; Bidard FC; Berman S; Fusco N; Sakr RA; Eberle CA; De Mattos-Arruda L; Macedo GS; Akram M; Baslan T; Hicks JB; King TA; Brogi E; Norton L; Weigelt B; Hudis CA; Reis-Filho JS
Clin Cancer Res; 2016 Aug; 22(16):4045-56. PubMed ID: 26960396
[TBL] [Abstract][Full Text] [Related]
15. Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990-2011.
Malmgren J; Hurlbert M; Atwood M; Kaplan HG
Breast Cancer Res Treat; 2019 Apr; 174(2):505-514. PubMed ID: 30560462
[TBL] [Abstract][Full Text] [Related]
16.
Lord SJ; Bahlmann K; O'Connell DL; Kiely BE; Daniels B; Pearson SA; Beith J; Bulsara MK; Houssami N
EClinicalMedicine; 2022 Feb; 44():101282. PubMed ID: 35128368
[TBL] [Abstract][Full Text] [Related]
17. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
Liang X; Vacher S; Boulai A; Bernard V; Baulande S; Bohec M; Bièche I; Lerebours F; Callens C
Breast Cancer Res; 2018 Aug; 20(1):88. PubMed ID: 30086764
[TBL] [Abstract][Full Text] [Related]
18. Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
McCarthy AM; Kumar NP; He W; Regan S; Welch M; Moy B; Iafrate AJ; Chan AT; Bardia A; Armstrong K
BMC Cancer; 2020 Apr; 20(1):347. PubMed ID: 32326897
[TBL] [Abstract][Full Text] [Related]
19. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
[TBL] [Abstract][Full Text] [Related]
20. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.
Kim HK; Park KH; Kim Y; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Lee JE; Ahn JS; Im YH; Yu JH; Park YH
Cancer Res Treat; 2019 Apr; 51(2):737-747. PubMed ID: 30189722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]